Plain-English translation of NCT06122077 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
The PROACT LUNG Study is testing a new blood test called the Freenome Multiomics Blood Test to see if it can help screen for lung cancer in people at high risk. This study will enroll 20,000 people and compare the blood test results to standard chest CT scans to see how well the medication performs in real-world settings.
Early detection of lung cancer saves lives, but current screening methods like chest CT scans are expensive and expose people to radiation. This trial aims to develop a simpler, safer blood test that could catch lung cancer earlier in people with significant smoking histories.
You likely qualify if…
You likely don't qualify if…
You will have a blood sample taken within 30 days of enrollment, ideally on the same day as a screening chest CT scan (though up to 45 days apart is allowed). The study team will collect your medical history, lifestyle information, and family history, and will follow you for at least 2 years to track any lung cancer diagnosis or related findings. You'll be asked to authorize release of your medical records and imaging reports related to lung health.
AI-generated summary from trial data · Jun 8, 2026 · Not medical advice
United States